Hikma Pharmaceuticals Plc (LON:HIK) declared a dividend on Friday, August 9th, Upcoming.Co.Uk reports. Stockholders of record on Thursday, August 22nd will be paid a dividend of $0.14 per share on Monday, September 23rd. This represents a dividend yield of 0.59%. The ex-dividend date of this dividend is Thursday, August 22nd. The official announcement can be seen at this link.
Shares of LON:HIK opened at GBX 2,058 ($26.89) on Tuesday. The company has a market capitalization of $4.97 billion and a price-to-earnings ratio of 13.83. The company has a debt-to-equity ratio of 37.69, a current ratio of 1.28 and a quick ratio of 0.78. The business’s 50-day moving average is GBX 1,847.32 and its 200-day moving average is GBX 1,740.74. Hikma Pharmaceuticals has a 1 year low of GBX 1,491.50 ($19.49) and a 1 year high of GBX 2,089 ($27.30).
A number of brokerages have recently issued reports on HIK. Peel Hunt reissued a “hold” rating and issued a GBX 2,050 ($26.79) price objective (up from GBX 1,870 ($24.43)) on shares of Hikma Pharmaceuticals in a research note on Friday, August 9th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a GBX 1,700 ($22.21) price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, June 18th. Finally, Barclays boosted their price objective on Hikma Pharmaceuticals from GBX 1,800 ($23.52) to GBX 1,900 ($24.83) and gave the company an “equal weight” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company’s stock. Hikma Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of GBX 1,848.57 ($24.15).
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.